A novel onco-miR-365 induces cutaneous squamous cell carcinoma

Carcinogenesis. 2013 Jul;34(7):1653-9. doi: 10.1093/carcin/bgt097. Epub 2013 Mar 20.

Abstract

The expression levels of miR-365 vary in different malignancies. Herein, we found that miR-365 was overexpressed in both cells and clinical specimens of cutaneous squamous cell carcinoma (SCC). We demonstrated that the HaCaT(pre-miR-365-2) cell line, which overexpressed miR-365, could induce subcutaneous tumors in vivo. Antagomir-365, an anti-miR-365 oligonucleotide, inhibited cutaneous tumor formation in vivo, along with G1 phase arrest and apoptosis of cancer cells. These findings suggest that miR-365 may act as an onco-miR in cutaneous SCC both in vitro and in vivo. The present study provides valuable insight into the role of miR-365 in cutaneous SCC formation, which can help develop new drug and miR-365 target-based therapies for cutaneous SCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Apoptosis
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy
  • Cell Line, Tumor
  • Female
  • G1 Phase Cell Cycle Checkpoints
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Middle Aged
  • Neoplasm Staging
  • Neoplasm Transplantation / pathology
  • Oligoribonucleotides, Antisense / administration & dosage
  • RNA, Neoplasm / genetics
  • RNA, Neoplasm / metabolism*
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • MIRN365 microRNA, human
  • MicroRNAs
  • Oligoribonucleotides, Antisense
  • RNA, Neoplasm